Yearly HIV prevention injection shows promise in clinical trial
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
MIT Technology Review4d
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Managed Healthcare Executive4d
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Healio3d
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Health and Me on MSN3d
Yearly Jab For HIV Protection Is Now Almost Here
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
STAT6d
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Fierce Pharma6d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
MedPage Today4d
Once-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly Dosing
"Once-yearly intramuscular lenacapavir for HIV PrEP has the potential to improve PrEP uptake and persistence and thus improve the scalability and public health impact of PrEP in populations who ...
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
Scientists develop yearly HIV injection: How it could help millions
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...